Stock CLPT CLEARPOINT NEURO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages ClearPoint Neuro, Inc.

Equities

CLPT

US18507C1036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
5.62 USD -2.09% Intraday chart for ClearPoint Neuro, Inc. +3.50% -17.23%
Jun. 04 ClearPoint Neuro, Inc. Initiates Its Full Market Release of the Smartframe CI
Jun. 01 Clearpoint Neuro Announces Full Market Release of Smartframe or and Clearpoint Prism 3T Laser Therapy System CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ClearPoint Neuro, Inc. Initiates Its Full Market Release of the Smartframe
Clearpoint Neuro Announces Full Market Release of Smartframe or and Clearpoint Prism 3T Laser Therapy System
ClearPoint Neuro, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory
ClearPoint Gets FDA Clearance For Neurosurgical Equipment
ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory
ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR? Stereotactic System
GNW-Adhoc: ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird
ClearPoint Neuro feliciteert partner AviadoBio met de behandeling van de eerste patiënt in klinisch onderzoek ASPIRE-FTD, waarin AVB-101 wordt geëvalueerd voor frontotemporale dementie met GRN-mutaties
ClearPoint Neuro si congratula con il proprio partner AviadoBio per il primo paziente trattato nello studio clinico ASPIRE-FTD, che valuta la terapia genica sperimentale AVB-101 per la demenza frontotemporale con mutazioni GRN
ClearPoint Neuro félicite son partenaire AviadoBio pour son premier patient traité dans le cadre de son essai clinique ASPIRE-FTD évaluant l’AVB-101 dans la démence fronto-temporale avec mutations du gène GRN
ClearPoint Neuro felicita a su socio AviadoBio por el primer paciente tratado en su ensayo clínico ASPIRE-FTD que evalúa AVB-101 en personas con demencia frontotemporal con mutaciones en el gen GRN
ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird
ClearPoint Neuro, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024
ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery
ClearPoint Neuro to Seek Acquisitions
ClearPoint Neuro, Inc. Announces FDA Clearance and First-In-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model
ClearPoint Neuro, Inc. Announces Installation and First Procedure Using the Clearpoint Prism® Neuro Laser Therapy System and Navigation System At Kaleida Health in Buffalo
GNW-Adhoc: ClearPoint Neuro gibt erste erfolgreiche EU-MDR-Zertifizierung und Genehmigung zur Lieferung von Produkten nach Europa bekannt
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLPT Stock
  4. News ClearPoint Neuro, Inc.
  5. Other languages